Form 4 for CRL Charles River Laboratories
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-29 · accession 0001127602-24-002765 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-31 | 2024-01-29 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | M - OptEx | $144.67 | +17.4K | 227.8K | +8% | +$2.52M |
| D | 2024-01-31 | 2024-01-29 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | F - Tax | $224.56 | -12.7K | 215.1K | -6% | -$2.85M |
| D | 2024-01-31 | 2024-01-29 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | M - OptEx | $0.00 | -17.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-29 | M | A | 17,436 | $144.67 | 227,827 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-29 | F | D | 12,710 | $224.56 | 215,117 | D | — | — | |
| 3 | Derivative | Stock Options (Right to Buy) | 2024-01-29 | M | D | 17,436 | $0.00 | 0 | D | $144.67 · 2020-02-22 to 2024-02-22 | 17,436 Common Stock | (F3) The transaction was executed as a net exercise, in which no shares were purchased or sold in the open market. |